Patents – Page 4
-
Business
FDA takes action to remove biosimilars roadblock
The US Food and Drug Administration proposes system to name biosimilar drugs
-
Business
Blast kills six at South Korean chemical plant
One further worker injured as tank explodes during welding work
-
Business
Teva fined $1.2bn in pay-for-delay case
Company illegally blocked generic competition of sleep disorder drug, and settlement terms tighten up rules on anticompetitive behaviour
-
Business
Actavis plan to thwart generics blocked
Company prevented from withdrawing original formulation of Alzheimer’s drug to force patients onto extended release version and extend patent exclusivity
-
Business
Injunction blocks first US biosimilar
Despite regulatory approval, Amgen is delaying sales of Sandoz’s version of filgrastim
-
FeatureCrossing the valley of death
Katrina Krämer examines efforts to bridge the gap between university research and commercial products
-
BusinessHepatitis C drug patent challenged in Europe
Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent
-
-
Business
EU warns DuPont and Honeywell over green refrigerants
Commission thinks cooperation may have been anti-competitive
-
Business
Amgen seeks injunction to protect patents
Sanofi and Regeneron sued over cholesterol-regulating antibodies
-
Business
Gilead licenses generic hepatitis C drug in India
Company aims to head off competition and grab a slice of royalties
-
Business
Cipla targets asthma market with Advair copy
Indian pharma company Cipla has launched a generic version of GSK’s best selling drug
-
BusinessLithium-ion battery makers look to stimulate electric car production
Tesla Motors opens up patents and manufacturers plan capacity increases
-
Business
Generics giants jostle over pain drug
Mylan and Actavis contest Teva’s generic celecoxib exclusivity
-
Business
Generics triumph in anti-inflammatory patent battle
Pfizer settles deals to allow copycat celecoxib
-
Business
Lilly wins cancer drug patent dispute
Alimta patent will last until 2022 after US court rules in Lilly’s favour
-
Business
Mitsui to close several Japanese plants and expand in China
Radical restructuring brings firm focus on speciality isocyanates
-
-
Business
AstraZeneca claims quashed in heartburn drug patent case
Nexium rival does not infringe on patent, court rules